Natural killer cell receptor complex

The "natural killer cell receptor complex" refers to the set of both **activating** and **inhibitory** receptors on the surface of natural killer (NK) cells, which mediate their recognition and elimination of target cells through a balance of signals. These receptors distinguish healthy from abnormal (infected or malignant) cells, primarily via recognition or absence of major histocompatibility complex (MHC) class I molecules and other stress- or transformation-induced ligands. Major groups within this complex include the **killer immunoglobulin-like receptors (KIRs)**, which are predominantly inhibitory and bind specific HLA class I molecules; **CD94/NKG2 receptors**, with both inhibitory (NKG2A) and activating (NKG2C/E/H) family members; **natural cytotoxicity receptors** such as NKp30, NKp44, and NKp46, which chiefly provide activation signals; and other activating receptors like **NKG2D** and **CD16 (FcγRIIIa)**. These receptors signal largely through immunoreceptor tyrosine-based activation/inhibition motifs (ITAMs/ITIMs) and adapter molecules such as DAP12 or CD3ζ, ultimately controlling NK cell cytotoxic function, cytokine production, and immunoregulatory roles[1][2][3][4][5][6][7][9]. Clarification/Issues (is_incorrect=true): "Natural killer cell receptor complex" is not the canonical name for a single molecular target. It collectively describes a family or group of related but distinct receptors rather than a specific, singular molecule. Each member (KIR, NKG2A, NKG2D, NKp30, NKp46, etc.) is separately considered a validated drug target, and more precise information should refer to individual receptor names and their unique characteristics[1][2][3].

Other names

NK cell receptorNK receptorNK cell surface receptorNK cell activating receptorNK cell inhibitory receptorKiller immunoglobulin-like receptorNatural cytotoxicity receptorNKG2 receptorLy49 receptorCD94/NKG2 receptor familyCD162B4 (CD244)

Immune checkpoint blockade; Modulation of NK cell activation/inhibition; Antibody-dependent cellular cytotoxicity (ADCC)